1 week Ago By ABMN Staff
Sei Investments Co. boosted its holdings in CareDx, Inc ( NASDAQ:CDNA – Free Report ) by 13.6% during the 4th quarter, Holdings Channel.
com reports. The fund owned 47,105 shares of the company’s stock after purchasing an additional 5,649 shares during the quarter. Sei Investments Co.
’s holdings in CareDx were worth $1,009,000 at the end of the most recent reporting period. Other institutional investors and hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in shares of CareDx by 2.
7% in the 3rd quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company’s stock worth $38,343,000 after purchasing an additional 32,141 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd.
boosted its holdings in CareDx by 25.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd.
now owns 875,197 shares of the company’s stock worth $18,738,000 after buying an additional 178,304 shares in the last quarter. FMR LLC grew its position in CareDx by 802.4% in the third quarter.
FMR LLC now owns 625,550 shares of the company’s stock worth $19,533,000 after buying an additional 556,230 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of CareDx by 2.
5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 511,922 shares of the company’s stock valued at $10,960,000 after buying an additional 12,442 shares in the last quarter.
Finally, Royce & Associates LP lifted its position in shares of CareDx by 23.1% during the 4th quarter. Royce & Associates LP now owns 484,286 shares of the company’s stock valued at $10,369,000 after acquiring an additional 91,000 shares during the last quarter.
CareDx Trading Up 2.5 % Shares of CareDx stock opened at $17.72 on Tuesday.
CareDx, Inc has a 1 year low of $7.42 and a 1 year high of $34.84.
The company has a market cap of $982.15 million, a P/E ratio of -6.56 and a beta of 2.
18. The stock has a 50-day moving average price of $20.80 and a 200 day moving average price of $23.
10. Analyst Ratings Changes CDNA has been the topic of a number of recent research reports. StockNews.
com upgraded CareDx from a “hold” rating to a “buy” rating in a report on Wednesday, February 26th. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and dropped their price target for the stock from $28.00 to $24.
00 in a research note on Wednesday, January 15th. HC Wainwright reduced their price objective on shares of CareDx from $26.00 to $25.
00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Finally, Stephens reissued an “overweight” rating and issued a $40.00 target price on shares of CareDx in a research report on Thursday, February 27th.
Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, CareDx presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.83.
View Our Latest Stock Analysis on CareDx About CareDx ( Free Report ) CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Featured Articles Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for CareDx, Inc ( NASDAQ:CDNA – Free Report ). Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter .
.
